Henan Newland Pharmaceutical Co. Ltd. A (301277) - Total Assets
Based on the latest financial reports, Henan Newland Pharmaceutical Co. Ltd. A (301277) holds total assets worth CN¥1.82 Billion CNY (≈ $266.71 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Henan Newland Pharmaceutical Co. Ltd. A - Total Assets Trend (2020–2025)
This chart illustrates how Henan Newland Pharmaceutical Co. Ltd. A's total assets have evolved over time, based on quarterly financial data. Also see how much is Henan Newland Pharmaceutical Co. Ltd. A worth for the company's overall valuation and market capitalisation.
Henan Newland Pharmaceutical Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2025)
Henan Newland Pharmaceutical Co. Ltd. A's total assets of CN¥1.82 Billion consist of 59.9% current assets and 40.1% non-current assets. Review total liabilities of Henan Newland Pharmaceutical Co. Ltd. A to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 9.5% |
| Accounts Receivable | CN¥130.97 Million | 7.4% |
| Inventory | CN¥72.37 Million | 4.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥49.99 Million | 2.8% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Henan Newland Pharmaceutical Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Henan Newland Pharmaceutical Co. Ltd. A stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Henan Newland Pharmaceutical Co. Ltd. A's current assets represent 59.9% of total assets in 2025, an increase from 51.4% in 2020.
- Cash Position: Cash and equivalents constituted 9.5% of total assets in 2025, up from 7.0% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 7.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 7.4% of total assets.
Henan Newland Pharmaceutical Co. Ltd. A Competitors by Total Assets
Key competitors of Henan Newland Pharmaceutical Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥53.34 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
|
Jiuzhitang Co Ltd
SHE:000989
|
China | CN¥5.73 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
Henan Newland Pharmaceutical Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.35 | 6.12 | 7.84 |
| Quick Ratio | 5.97 | 5.95 | 7.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥931.71 Million | CN¥965.72 Million | CN¥1.05 Billion |
Henan Newland Pharmaceutical Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Henan Newland Pharmaceutical Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.80 |
| Latest Market Cap to Assets Ratio | 0.32 |
| Asset Growth Rate (YoY) | -1.9% |
| Total Assets | CN¥1.78 Billion |
| Market Capitalization | $565.70 Million USD |
Valuation Analysis
Below Book Valuation: The market values Henan Newland Pharmaceutical Co. Ltd. A's assets below their book value (0.32x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Henan Newland Pharmaceutical Co. Ltd. A's assets decreased by 1.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Henan Newland Pharmaceutical Co. Ltd. A (2020–2025)
The table below shows the annual total assets of Henan Newland Pharmaceutical Co. Ltd. A from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.78 Billion ≈ $260.40 Million |
-1.89% |
| 2024-12-31 | CN¥1.81 Billion ≈ $265.41 Million |
+12.69% |
| 2023-12-31 | CN¥1.61 Billion ≈ $235.52 Million |
+4.94% |
| 2022-12-31 | CN¥1.53 Billion ≈ $224.44 Million |
+129.64% |
| 2021-12-31 | CN¥667.90 Million ≈ $97.74 Million |
+27.96% |
| 2020-12-31 | CN¥521.96 Million ≈ $76.38 Million |
-- |
About Henan Newland Pharmaceutical Co. Ltd. A
Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. The company offers pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. It also provides APIs, such as ropivacaine hydrochloride, naph… Read more